Xvivo Perfusion AB Cash Flow Conversion Efficiency
Xvivo Perfusion AB cash flow conversion efficiency. Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has a cash flow conversion efficiency ratio of 0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr63.49 Million ≈ $6.83 Million USD) by net assets (Skr2.20 Billion ≈ $236.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Xvivo Perfusion AB (XVIVO) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Xvivo Perfusion AB (2011–2025)
Cash flow conversion efficiency of Xvivo Perfusion AB from 2011 to 2025. This chart illustrates how Xvivo Perfusion AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Xvivo Perfusion AB share price for real-time trading data and today's change.
Xvivo Perfusion AB Cash Flow Conversion Ratio Explained
Xvivo Perfusion AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xvivo Perfusion AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xvivo Perfusion AB ranked by their cash flow conversion efficiency. Review Xvivo Perfusion AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tong Oil Tools
SHE:300164
|
0.020x |
|
Bassac
PA:BASS
|
-0.009x |
|
Lsb Industries Inc
NYSE:LXU
|
0.111x |
|
China CYTS Tours Holding Co Ltd
SHG:600138
|
0.044x |
|
Anhui Tongfeng Electronics Co Ltd
SHG:600237
|
0.024x |
|
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
STU:2TZ
|
-0.009x |
|
Taiwan Semiconductor Co Ltd
TWO:5425
|
0.014x |
|
Cita Mineral Investindo Tbk PT
JK:CITA
|
0.043x |
Annual Cash Flow Conversion Efficiency for Xvivo Perfusion AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Xvivo Perfusion AB from 2011 to 2025. Also see balance sheet size of Xvivo Perfusion AB for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr2.11 Billion ≈ $227.44 Million |
Skr101.07 Million ≈ $10.88 Million |
0.048x | -7.33% |
| 2024-12-31 | Skr2.16 Billion ≈ $232.10 Million |
Skr111.29 Million ≈ $11.98 Million |
0.052x | +116.83% |
| 2023-12-31 | Skr1.95 Billion ≈ $209.32 Million |
Skr46.29 Million ≈ $4.98 Million |
0.024x | +22.18% |
| 2022-12-31 | Skr1.43 Billion ≈ $153.91 Million |
Skr27.86 Million ≈ $3.00 Million |
0.019x | +307.63% |
| 2021-12-31 | Skr1.29 Billion ≈ $138.33 Million |
Skr-12.06 Million ≈ $-1.30 Million |
-0.009x | +22.87% |
| 2020-12-31 | Skr1.01 Billion ≈ $108.53 Million |
Skr-12.27 Million ≈ $-1.32 Million |
-0.012x | -123.81% |
| 2019-12-31 | Skr577.52 Million ≈ $62.15 Million |
Skr29.50 Million ≈ $3.18 Million |
0.051x | +16.87% |
| 2018-12-31 | Skr540.48 Million ≈ $58.16 Million |
Skr23.63 Million ≈ $2.54 Million |
0.044x | -0.64% |
| 2017-12-31 | Skr504.33 Million ≈ $54.27 Million |
Skr22.19 Million ≈ $2.39 Million |
0.044x | +10.93% |
| 2016-12-31 | Skr316.41 Million ≈ $34.05 Million |
Skr12.55 Million ≈ $1.35 Million |
0.040x | -14.52% |
| 2015-12-31 | Skr184.87 Million ≈ $19.90 Million |
Skr8.58 Million ≈ $923.13K |
0.046x | +318.52% |
| 2014-12-31 | Skr176.18 Million ≈ $18.96 Million |
Skr-3.74 Million ≈ $-402.59K |
-0.021x | -115.24% |
| 2013-12-31 | Skr96.64 Million ≈ $10.40 Million |
Skr13.46 Million ≈ $1.45 Million |
0.139x | +641.01% |
| 2012-12-31 | Skr88.77 Million ≈ $9.55 Million |
Skr1.67 Million ≈ $179.61K |
0.019x | -98.42% |
| 2011-12-31 | Skr11.91 Million ≈ $1.28 Million |
Skr14.17 Million ≈ $1.52 Million |
1.190x | -- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more